echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Will this AI prediction product, launched by IBM and Pfizer, change the status quo for Alzheimer's diagnosis and treatment?

    Will this AI prediction product, launched by IBM and Pfizer, change the status quo for Alzheimer's diagnosis and treatment?

    • Last Update: 2020-11-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Alzheimer's disease (AD), also known as Alzheimer's disease, is a neurogenic degenerative disease that develops implicitly, with an average survival of 5.5 years.
    although the disease is more common in people over 70 years of age, symptoms and reactions actually begin as early as middle age.
    there is currently no cure for Alzheimer's disease, so early detection and treatment is key to dealing with the disease.
    recently, Pfizer Inc., the U.S. drug giant, and IBM Corp., an IT giant, published an article in The Lancet Magazine Media entitled Linguistic markers predictive of the discovery of Alzheimer's disease, created an intelligent alternative to the early detection of Alzheimer's disease.
    the two companies' joint artificial intelligence (AI) models can help predict the eventual onset of Alzheimer's disease with 71% accuracy based on language samples, according to the paper.
    doi.org/10.1016/j.eclinm.2020.100583 previously, IBM had tested artificial intelligence to identify proteins to predict the reliability of β amyloid concentrations, and other studies were working on ways to predict the progression of Alzheimer's disease.
    ibm and Pfizer's study differs from previous studies in that it is based on data collected before subjects first developed symptoms of cognitive impairment, and also assesses the risk of Alzheimer's disease in the general population rather than high-risk groups.
    specifically, the study aims to test the extent to which people's ability to express language on a single time node can be used as a prognostic indicator of their future conversion to AD.
    researchers analyzed 703 samples from 270 participants using data from the Framingham Heart Study, which began in 1948.
    Language analysis included 87 variables, including more than misspellings, length, vocabulary richness and repeatability, taking into account assessments of age, gender, educational attence, visual space, and executive reasoning.
    of case and control selection and predicting model settings.
    the researchers tested voice samples from 80 subjects before the participants showed signs of cognitive decline.
    Final results showed that half of these participants developed AD before the age of 85, and the language variables most associated with predicting AD seizures were telegram speech (grammatical problems), repetitive and misspelling errors, with an average time of 7.59 years from cognitive normality to mild AD diagnosis and 3.93 years from cognitive normality to cognitive impairment.
    that such tests do not necessarily replace today's clinical standards, but can be used as an early procedure to recommend brain scans.
    , the study may play a key role in helping to develop new AD therapies that could help drug developers design better Alzheimer's trials. Ajay Royyuru,
    IBM researcher and vice president of healthcare and life sciences research at IBM, said: "Looking back at past failures in alzheimer's drug development, it can be found that most of the patients recruited are in the process of developing the disease, and that digital biomarkers that can quantitatively assess a person's disease progression will undoubtedly help drug developers design better Alzheimer's trials."
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.